IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+2.33%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$903M
AUM Growth
+$903M
(-20%)
Cap. Flow
-$189M
Cap. Flow
% of AUM
-20.9%
Top 10 Holdings %
Top 10 Hldgs %
48.7%
Holding
109
New
26
Increased
18
Reduced
25
Closed
31
Top Buys
| 1 |
Elevance Health
ELV
|
$28.3M |
| 2 |
Novartis
NVS
|
$27.9M |
| 3 |
Mineralys Therapeutics
MLYS
|
$22.6M |
| 4 |
Baxter International
BAX
|
$17.1M |
| 5 |
Ascendis Pharma
ASND
|
$15.6M |
Top Sells
| 1 |
Centene
CNC
|
$30.3M |
| 2 |
Cardinal Health
CAH
|
$29.6M |
| 3 |
Eli Lilly
LLY
|
$29.3M |
| 4 |
Intuitive Surgical
ISRG
|
$20.9M |
| 5 |
CVS Health
CVS
|
$20.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Inspire Medical Systems
INSP
$2.55B
| $10.4M | 1.1% |
65,000
-35,000
| -35% | -$5.57M |
|
27
Tarsus Pharmaceuticals
TARS
$2.44B
| $10.3M | 1.09% |
200,000
-150,000
| -43% | -$7.71M |
|
28
Penumbra
PEN
$10.5B
| $9.36M | 1% |
+35,000
| New | +$9.36M |
|
29
Edwards Lifesciences
EW
$47.6B
| $9.06M | 0.96% |
+125,000
| New | +$9.06M |
|
30
Revolution Medicines
RVMD
$7.42B
| $8.84M | 0.94% |
250,000
-300,000
| -55% | -$10.6M |
|
31
McKesson
MCK
$85.6B
| $8.08M | 0.86% |
12,000
-23,000
| -66% | -$15.5M |
|
32
MoonLake Immunotherapeutics
MLTX
$3.8B
| $7.81M | 0.83% |
200,000
| – | – |
|
33
Teva Pharmaceuticals
TEVA
$21.4B
| $7.69M | 0.82% |
500,000
| – | – |
|
34
89bio
ETNB
$1.36B
| $7.63M | 0.81% |
1,050,000
+50,000
| +5% | +$364K |
|
35
Pfizer
PFE
$141B
| $7.6M | 0.81% |
+300,000
| New | +$7.6M |
|
36
Acadia Healthcare
ACHC
$2.15B
| $7.58M | 0.81% |
250,000
-50,000
| -17% | -$1.52M |
|
37
Masimo
MASI
$7.4B
| $7.5M | 0.8% |
+45,000
| New | +$7.5M |
|
38
Waters Corp
WAT
$17.4B
| $7.37M | 0.78% |
20,000
-10,000
| -33% | -$3.69M |
|
|
VRNA
39
Verona Pharma
VRNA
$9.18B
| $7.3M | 0.78% |
+115,000
| New | +$7.3M |
|
40
DexCom
DXCM
$29.9B
| $6.83M | 0.73% |
100,000
-50,000
| -33% | -$3.41M |
|
41
Regenxbio
RGNX
$465M
| $6.61M | 0.7% |
925,000
+25,000
| +3% | +$179K |
|
42
Bristol-Myers Squibb
BMY
$96.8B
| $6.1M | 0.65% |
100,000
-250,000
| -71% | -$15.2M |
|
43
Roivant Sciences
ROIV
$8.47B
| $6.05M | 0.64% |
+600,000
| New | +$6.05M |
|
44
Protara Therapeutics
TARA
$125M
| $5.96M | 0.63% |
1,400,000
| – | – |
|
45
IQVIA
IQV
$31B
| $5.29M | 0.56% |
+30,000
| New | +$5.29M |
|
46
CRISPR Therapeutics
CRSP
$4.82B
| $5.1M | 0.54% |
+150,000
| New | +$5.1M |
|
47
PTC Therapeutics
PTCT
$4.33B
| $5.1M | 0.54% |
+100,000
| New | +$5.1M |
|
48
Alkermes
ALKS
$4.99B
| $4.95M | 0.53% |
+150,000
| New | +$4.95M |
|
49
Dyne Therapeutics
DYN
$1.89B
| $4.71M | 0.5% |
450,000
+300,000
| +200% | +$3.14M |
|
50
Labcorp
LH
$22.6B
| $4.65M | 0.5% |
+20,000
| New | +$4.65M |
|